Amarin Corporation PLC is a pharmaceutical company. The Company is focused on the commercialization and development of therapeutics to improve cardiovascular (CV), health and reduce CV risk. The Company operates through the development and commercialization of VASCEPA. Its lead product, Vascepa (icosapent ethyl) capsule is used as an adjunct to diet to reduce triglyceride levels in adult patients with severe hypertriglyceridemia. This indication for Vascepa, known as the MARINE indication, is based primarily on the results from the MARINE study of Vascepa in this approved patient population. The Company sells Vascepa principally to wholesalers, as well as selected regional wholesalers and specialty pharmacy providers, or collectively, its distributors, which in turn resell Vascepa to retail pharmacies for resale to patients and healthcare providers.

Employees

Sector

Biotechnology & Medical Research

More about the company

07-29	Amarin Corporation plc, Q2 2026 Earnings Call, Jul 29, 2026
07-29	European Equities Traded in US as ADRs Ease in Wednesday Trading	MT

Market Cap	299M 260M 242M 222M 419M 28.47B 427M 2.86B 1.12B 14.2B 1.12B 1.1B 46.83B	P/E 2026 *	-202x	P/E 2027 *	-236x
Enterprise Value	143M 124M 116M 106M 200M 13.59B 204M 1.36B 534M 6.78B 536M 524M 22.35B	EV / Sales 2026 *	0.83x	EV / Sales 2027 *	0.87x
Free-Float	86.93%	Yield 2026 *	-	Yield 2027 *	-

07-29	Amarin Corporation plc, Q2 2026 Earnings Call, Jul 29, 2026
07-29	European Equities Traded in US as ADRs Ease in Wednesday Trading	MT
07-29	Amarin Corporation plc Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI
07-02	European Equities Traded in the US as American Depositary Receipts Rise Sharply in Thursday Trading	MT
06-30	Amarin Corporation plc Reaffirms the Proven Guideline-Recommended Role of Vascepa (Icosapent Ethyl) in an Evolving Triglyceride Treatment Landscape	CI
06-29	European Equities Traded in the US as American Depositary Receipts Track Higher in Monday Trading	MT
06-23	Top cases on the US Supreme Court's docket	RE
06-22	European Equities Traded in the US as American Depositary Receipts Rise in Monday Trading	MT
06-18	European Equities Traded in the US as American Depositary Receipts Little Changed in Thursday Trading	MT
06-09	European Equities Traded in the US as American Depositary Receipts Track Higher in Tuesday Trading	MT
06-08	European Equities Traded in the US as American Depositary Receipts Start Week Higher in Monday Trading	MT
06-05	The Jobs Report Just Made the Fed's Life Harder
06-05	To infinity and beyond

27/10/25	Amarin issues statement supporting FDA's action to revise labeling for fenofibrate drugs reinforcing a lack of cardiovascular benefit	RE
25/06/25	RBC Ups Recordati's Price Target on Cardiovascular Drug European Licensing Deal	MT
25/10/23	Jefferies Downgrades Amarin to Hold From Buy, Cuts Price Target to $1 From $3	MT
19/07/23	Northland Adjusts Price Target on Amarin to $1.25 From $2, Maintains Market Perform Rating	MT
06/01/23	Jefferies Upgrades Amarin to Buy From Hold, Adjusts Price Target to $3 From $1.30	MT

07-29	Amarin: Q2 Earnings Snapshot	AQ
07-29	Amarin Reports 2026 Second Quarter Financial Results Demonstrating Early Success of Fully Partnered International Commercial Strategy and Continued Leading U.S. Market Presence	AQ
07-15	Amarin to Report Second Quarter 2026 Financial Results and Host Conference Call on July 29, 2026	AQ
06-30	Amarin Reaffirms the Proven, Guideline-Recommended Role of VASCEPA® (Icosapent Ethyl) in an Evolving Triglyceride Treatment Landscape	AQ
05-27	New REDUCE-IT® Analysis Presented at the European Atherosclerosis Society (EAS) Congress 2026 Suggests Risk-Weighted ApoB May Improve Identification of Residual Cardiovascular Risk in Statin-Treated Patients with Hypertriglyceridemia	AQ

Amarin Corporation plc (ADR) Share Price Xetra

Stocks

EH3A

US0231112063

Biotechnology & Medical Research

Valuation: Amarin Corporation plc (ADR)

Latest news : Amarin Corporation plc (ADR)

Last Transcript: Amarin Corporation plc (ADR)

Analysts' recommendations: Amarin Corporation plc (ADR)

Press Releases: Amarin Corporation plc (ADR)

News in other languages: Amarin Corporation plc (ADR)

Managers and Directors: Amarin Corporation plc (ADR)

Bio Therapeutic Drugs

Financials

Company Profile

06-05	Afternoon Meeting: Los datos de empleo complican la labor de la Fed
06-05	Bourse : Lululemon dévisse, Blackstone se protège, Schneider émet 850 MEUR d'OCEANE
29/07/25	Recordati : firmato contratto di licenza e fornitura con Amarin per 25mln $ (RCO)
24/06/25	Recordati e Amarin commercializzano il farmaco cardiovascolare Vazkepa
29/03/22	Amarin reçoit un remboursement pour VAZKEPA® en Suède

Manager	Title	Age	Since
Aaron Berg CEO	Chief Executive Officer	63	03/06/2024
Peter Fishman DFI	Director of Finance/CFO	42	22/10/2024
Jonathan Provoost CMP	Compliance Officer	56	14/11/2023

Director	Title	Age	Since
Aaron Berg BRD	Director/Board Member	63	03/06/2024
Patrice Bonfiglio BRD	Director/Board Member	43	27/02/2023
Keith Horn BRD	Director/Board Member	67	27/02/2023

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
WUXI APPTEC CO., LTD.	+0.05%	+3.08%	+38.17%	+66.77%	56.7B
ARGENX SE	+0.58%	-5.91%	+23.62%	+62.29%	51.97B
BIONTECH SE	+1.84%	+1.27%	-14.06%	-13.50%	23.33B
INSMED INCORPORATED	-0.15%	-6.00%	-9.42%	+344.47%	21.34B
GENMAB A/S	+1.19%	-1.97%	+32.28%	-26.10%	17.44B
PHARMAESSENTIA CORPORATION	+9.91%	-2.51%	+188.84%	+326.19%	14.77B
EXELIXIS, INC.	+3.83%	-1.34%	+47.77%	+165.22%	13.84B
ARROWHEAD PHARMACEUTICALS, INC.	+1.61%	+0.56%	+439.92%	+166.12%	12.12B
MADRIGAL PHARMACEUTICALS, INC.	+3.14%	-12.56%	+59.51%	+149.39%	11.14B
Average	+2.45%	-2.33%	+89.63%	+137.87%	24.74B
Weighted average by Cap.	+1.56%	-1.95%	+57.80%	+109.53%

	2026 *	2027 *
Net sales	172M 149M 139M 128M 241M 16.35B 245M 1.64B 643M 8.15B 644M 630M 26.89B	165M 143M 134M 123M 231M 15.69B 235M 1.58B 617M 7.83B 618M 605M 25.81B
Net income	-29.68M -25.79M -24.08M -22.11M -41.69M -2.83B -42.41M -284M -111M -1.41B -111M -109M -4.65B	-23.48M -20.41M -19.05M -17.49M -32.98M -2.24B -33.55M -225M -87.98M -1.12B -88.2M -86.24M -3.68B
Net Debt	-156M -136M -127M -116M -219M -14.88B -223M -1.49B -585M -7.42B -586M -573M -24.47B	-156M -135M -126M -116M -219M -14.85B -223M -1.49B -584M -7.4B -585M -572M -24.42B

End-of-day quote Xetra Other stock markets
- ^EUR	-